This is a working overview of peptide mapping, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-10 and is reviewed periodically as new material appears.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
== Safety and the environment == Indigo has a low oral toxicity, with an LD50 of 5 g/kg (0.5% of total mass) in mammals. In 2009, large spills of blue dye were reported downstream of a blue jeans manufacturer in Lesotho. The compound has been found to act as an agonist of the aryl hydrocarbon receptor.
== Cast == Lisa Sanders — physician, narrator, and columnist for The New York Times. Angel Parker — a 23-year-old nursing student from Las Vegas, Nevada. Her symptoms include episodes of severe muscle painthat render her immobile. Sadie Gonzalez — a 7-year-old girl from Queens, New York. She suffers from hundreds of seizures daily. Physicians initially suggest removing a large part of her brain (a hemispherectomy) as a form of treatment. Willie Reyes — a 46-year-old Army veteran from Vado, New Mexico. He suffers from frequent seizures that result in memory loss and mood swings. Kamiyah Morgan — a 6-year-old girl from Vermillion, South Dakota. She has frequent fainting episodes that can happen up to 300 times a day; these cause her to temporarily go limp and unresponsive. Lashay Hamblin — a 16-year-old high school student from South Jordan, Utah. She cannot keep down any foods or liquids but does not have bulimia. Matt Lee — a 20-year-old college student from Mt. Airy, Maryland. He suffers from frequent fainting spells that occur when he feels a sense of deja vu. These fainting spells also cause his heart to momentarily stop. Joe — a 61-year-old man from Wallingford, Connecticut. He was struck with a sudden and unexplained paralysis from his waist down, leaving him paraplegic. Ann — a 42-year-old patient from Wallingford, CT. She has intermittent paralysis affecting the right side of her body. She will regain mobility but the paralysis always occurs again.
Members of the parliament of the Free State would be required to take an oath of allegiance to the Constitution of the Free State and to declare that they would be "faithful" to the king (a modification of the oath taken in other dominions). The Second Dáil ratified the Treaty on 7 January 1922, causing a split in the republican movement. A Provisional Government was formed, with Michael Collins as chairman. The Free State was established on 6 December 1922, and the Provisional Government became the Executive Council of the Irish Free State, headed by W. T. Cosgrave as President of the Executive Council. The following day, the Commons and the Senate of Northern Ireland passed resolutions "for the express purpose of opting out of the Free State". Two days after the founding of the Irish Free State, anti-Treaty IRA members opened fire on Seán Hales and Pádraic Ó Máille, both Teachtaí Dála (TDs), as they were leaving the Dáil. Hales was killed, while Ó Máille was seriously wounded. On 8 December 1922, four imprisoned leaders of the anti-treaty IRA (Liam Mellows, Rory O'Connor, Joe McKelvey and Dick Barrett) were executed in retaliation for the killing of Hales.
== Toxicity == Studies of the acute and chronic toxicity of lithium ascorbate have shown that lithium ascorbate is characterized by an extremely low acute and chronic toxicity. In acute toxicity studies with a single dose of 3000 mg/kg of lithium ascorbate, mortality was 0%, no pathological changes were found, as well as signs of local irritant action. At 4000 mg/kg, mortality (delayed) was 20%. Intoxication in males was manifested as oppression, diarrhea, ruffled hair, bloody discharge from the nose and eyes, in females - diarrhea. Pathological changes included plethora of the meninges, edema and plethora of the lungs, hemorrhages in the lungs. For Wistar rats LD50 of lithium ascorbate was 6334 mg/kg of body weight, and LD100 was 8000 mg/kg. Thus, lithium ascorbate can be classified as class 5 "practically non-toxic compounds" (LD50> 5000 mg/kg). Compared with lithium carbonate (LD50 = 531 mg/kg), lithium ascorbate is 12 times less toxic. It is known that the anion, which forms a lithium salt, is one of the most significant factors affecting the toxicity of the salt. For example, for rats, the LD50 of lithium chloride when administered orally is 1530 mg/kg, and when administered intraperitoneally it is 925 mg/kg. For rabbits, the LD50 of the same salt is 775 mg/kg orally. The greatest acute toxicity was established for lithium fluoride (LD50=175 mg/kg, for mice), while bromide, nicotinate, oxybutyrate are much less toxic (LD50 for mice - 2200 mg/kg).
Pauling did, however, work on research for the military. He was a principal investigator on 14 OSRD contracts. The National Defense Research Committee called a meeting on October 3, 1940, wanting an instrument that could reliably measure oxygen content in a mixture of gases, so that they could measure oxygen conditions in submarines and airplanes. In response Pauling designed the Pauling oxygen meter, which was developed and manufactured by Arnold O. Beckman, Inc. After the war, Beckman adapted the oxygen analyzers for use in incubators for premature babies. In 1942, Pauling successfully submitted a proposal on "The Chemical Treatment of Protein Solutions in the Attempt to Find a Substitute for Human Serum for Transfusions". His project group, which included Joseph B. Koepfli and Dan H. Campbell, developed a possible replacement for human blood plasma in transfusions: polyoxy gelatin (Oxypolygelatin). Other wartime projects with more direct military applications included work on explosives, rocket propellants and the patent for an armor-piercing shell. In October 1948, Pauling, along with Lee A. DuBridge, William A. Fowler, Max Mason, and Bruce H. Sage, was awarded a Presidential Medal for Merit by President Harry S. Truman. The citation credits him for his "imaginative mind", "brilliant success", and "exceptionally meritorious conduct in the performance of outstanding services". In 1949, he served as president of the American Chemical Society.
Sources: en.wikipedia.org
Bill Rosenberg opened the Open Kettle in 1948, a restaurant selling doughnuts and coffee in Quincy, Massachusetts (a suburb of Boston), but in late May 1950, he changed the name to Dunkin' Donuts after discussions with company executives. He conceived the idea for the restaurant after his experiences selling food in factories and at construction sites, where doughnuts and coffee were the two most popular items. The company introduced its first logo in 1953, and the mascot Dunkie in 1954. The restaurant was successful, and Rosenberg sold franchises to others starting in 1955. It was during this time that Johnny Spartos, one of the men running the original Quincy location, convinced Rosenberg to produce a donut with a handle specifically for dunking into a cup of coffee.
Although nominally a "defensive" alliance, the Pact's primary function was to safeguard the Soviet Union's hegemony over its Eastern European satellites, with the Pact's only direct military actions having been the invasions of its own member states to keep them from breaking away. The Cominform (1947–1956), informally the Communist Information Bureau and officially the Information Bureau of the Communist and Workers' Parties, was the first official agency of the international Marxist-Leninist movement since the dissolution of the Comintern in 1943. Its role was to coordinate actions between Marxist-Leninist parties under Soviet direction. Stalin used it to order Western European communist parties to abandon their exclusively parliamentarian line and instead concentrate on politically impeding the operations of the Marshall Plan, the U.S. program of rebuilding Europe after the war and developing its economy. It also coordinated international aid to Marxist-Leninist insurgents during the Greek Civil War in 1947–1949. It expelled Yugoslavia in 1948 after Josip Broz Tito insisted on an independent program. Its newspaper, For a Lasting Peace, for a People's Democracy!, promoted Stalin's positions. The Cominform's concentration on Europe meant a deemphasis on world revolution in Soviet foreign policy. By enunciating a uniform ideology, it allowed the constituent parties to focus on personalities rather than issues.
==== Anima and animus ==== Jung argued that the unconscious of every man contains a complementary feminine element (the anima) and every woman a complementary masculine element (the animus). Within these complementary elements exist an inherited collective image of 'man' and 'woman' respectively, which only becomes conscious in actual contacts with men and women. As such, these are archetypes of the collective unconscious. These counterparts come in part from this inherited collective image, but also partly through a person's contact with the opposite gender in their life (particularly their parental figures), and partly through the latent masculinity (for women) and femininity (for men) that a person experiences in themselves. Like the shadow, if a person rejects their anima or animus, it is more likely to be projected outwards.
The port is accessible by road from the M20/A20 (leading to Folkestone) and the M2/A2 (to Canterbury), and by train from Dover Priory station with Southeastern services to London St Pancras via Folkestone Central, Ashford International, Ebbsfleet International, Stratford International as well as trains to London Victoria or London Charing Cross via Canterbury East and the Medway towns such as Gillingham, Chatham and Rochester or via Ashford International then either via Tonbridge and Sevenoaks or Maidstone East. There are trains to Deal and Ramsgate.
=== Storage of potatoes === Various storage conditions can have an impact on the level of solanine in potatoes. Glycoalkaloid levels increase when potatoes are exposed to light because light increases synthesis of glycoalkaloids like solanine. Potatoes stored in a dark place avoid increased solanine synthesis. Potatoes that have turned green due to increased chlorophyll and photosynthesis are indicative of increased light exposure and are therefore associated with high levels of solanine. Synthesis of solanine is also stimulated by mechanical injury because glycoalkaloids are synthesized at cut surfaces of potatoes. Storage of potatoes for extended periods of time has also been associated with increased solanine content. A study found that the solanine levels in Kufri Jyoti and Kufri Giriraj potatoes increase solanine levels by 0.232 mg/g and 0.252 mg/g respectively after being poorly stored in a heap.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.